Anabolic-androgenic steroids promote risky decision making

University Of Southern California, Los Angeles CA

Investigators

Linked publications & trials

Abstract

? DESCRIPTION (provided by applicant): Although anabolic-androgenic steroids (AAS) have legitimate medical uses, they are also drugs of abuse. AAS are taken in large quantities by athletes and others to increase performance, with negative long- term health consequences. In 1991, testosterone was declared a controlled substance. Nonetheless, illicit use of AAS continues to increase, particularly among adolescents. Indeed, the incidence of steroid use among high school seniors is comparable to that for cocaine or heroin. Although users defend performance enhancing substances as a healthy lifestyle choice, clinical studies and anecdotal reports present a different picture. Many AAS users meet DSM criteria for psychoactive substance dependence, including continued use despite negative side effects, and withdrawal symptoms when steroids are discontinued. Ultimately, unlike other illicit drugs, AAS have only a limited capacity for acute intoxication. Instead, a key danger of AAS abuse reflects the likelihood that users will engage in behaviors that pose risks to themselves and those around them. Understanding behavioral effects of AAS use in humans is complicated by the user's motivation for increased strength and muscle mass. Furthermore, we cannot control for preexisting psychopathology or for variability in the type or dose of AAS, and it is unethical to test high doses of AAS in normal volunteers. Animal studies can evaluate responses to AAS in an experimental context where appearance and athletic performance are irrelevant. Therefore, we use rats treated chronically with high-dose testosterone to model human AAS use. In humans, AAS increase risk-taking: fighting, unsafe sex, drinking and driving, carrying a weapon. Our studies in rats demonstrate that AAS separately modify decision making on tests of effort, punishment, delay and probability discounting. The proposed studies will build on these recent findings to test the hypothesis that AAS impair complex decision making and cooperation, and these effects are mediated by dopamine (DA) acting via D1- (D1R) and D2-like receptors (D2R) in subnuclei of the nucleus accumbens (Acb). In operant discounting tasks, rats choose between a small reward (1 sugar pellet) vs a large reward (3-4 pellets) which is discounted (made less desirable) by some cost. Chronic high-dose testosterone makes rats less sensitive to physical effort, punishment or delay, but more sensitive to uncertainty. Studies in Aim 1 go beyond simple discounting tasks to model decision-making in a natural environment, presenting cognitively-demanding choices with conflicting costs, and incorporating social interaction. Aim 2 will explore neurobiologic mechanisms for impaired decision making with AAS. As part of the mesolimbic DA system, Acb is central to motivated behavior and decision-making, and DA dysfunction impairs decision making. We will test intra-Acb implants of testosterone (Aim 2A), and pharmacologic manipulation of DAR in Acb during effort- and probability discounting (Aim 2B) and reciprocal cooperation (Aim 2C). Together, these studies will provide insight into the cognitive changes induced by AAS, and the mechanisms through which these occur.